Inhibikase Therapeutics's total assets for Q3 2024 were $4.38M, a decrease of -50.41% from the previous quarter. IKT total liabilities were $4.91M for the fiscal quarter, a 31.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.